[1] Dores GM, Devesa SS, Curtis RE, et al. Acute leukemia incidence and patient survival among children and adults in the United States, 20012007[J]. Blood, 2012, 119(1):3443.
[2] Kobayashi R, Tawa A, Hanada R, et al. Extramedullary infiltration at diagnosis and prognosis in children with acute myelogenous leukemia[J]. Pediatr Blood Cancer, 2007, 48(4):393398.
[3] Yang LL, Gan SL, Liu YF, et al. Clinical characteristics of CD56(+) patients with acute monocytic leukemia and their prognostic significance[J]. Zhongguo Shi Yan Xue Ye Xue Za Zhi, 2013, 21(3):596600.
[4] Shimizu H, Saitoh T, Hatsumi N, et al. Prevalence of extramedullary relapses is higher after allogeneic stem cell transplantation than after chemotherapy in adult patients with acute myeloid leukemia[J]. Leuk Res, 2013, 37(11):14771481.
[5] Ge L, Ye F, Mao X, et al. Extramedullary relapse of acute leukemia after allogeneic hematopoietic stem cell transplantation: different characteristics between acutemyelogenous leukemia and acute lymphoblastic leukemia[J].Biol Blood Marrow Transplant,2014, 20(7): 10401047.
[6] Jacamo R, Chen Y, Wang Z, et al. Reciprocal leukemiastroma VCAM1/VLA4dependent activation of NFkappaB mediates chemoresistance[J]. Blood, 2014, 123(17):26912702.
[7] Ishikawa F, Yoshida S, Saito Y, et al. Chemotherapyresistant human AML stem cells home to and engraft within the bonemarrow endosteal region[J]. Nat Biotechnol, 2007, 25(11):13151321.
[8] Saito Y, Uchida N, Tanaka S, et al. Induction of cell cycle entry eliminates human leukemia stem cells in a mouse model of AML[J]. Nat Biotechnol, 2010, 28(3):275280.
[9] Borowitz MJ, Devidas M, Hunger SP, et al. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children′s Oncology Group study[J]. Blood, 2008, 111(12):54775485.
[10] Kato I, Niwa A, Heike T, et al. Identification of hepatic niche harboring human acute lymphoblastic leukemic cells via the SDF1/CXCR4 axis[J]. PLoS One, 2011, 6(11):e27042.
[11] 马玉花,邹亚伟. 白血病肝损伤的研究进展[J]. 中国小儿血液与肿瘤杂志,2013, 18(2):9396.
[12] Schemionek M, Spieker T, Kerstiens L, et al. Leukemic spleen cells are more potent than bone marrowderived cells in a transgenic mouse model of CML[J]. Leukemia, 2012, 26(5):10301037.
[13] Sengupta A, Arnett J, Dunn S, et al. Rac2 GTPase deficiency depletes BCRABL+ leukemic stem cells and progenitors in vivo[J]. Blood, 2010, 116(1):8184.
[14] Shaked Y, Cervi D, Neuman M, et al. The splenic microenvironment is a source of proangiogenesis/inflammatory mediators accelerating the expansion of murine erythroleukemic cells[J]. Blood, 2005, 105(11):45004507.
[15] Feng SR, Chen ZX, Cen JN, et al. Disruption of blood brainbarrier by leukemic cells in central nervous system leukemia[J]. Zhonghua Xue Ye Xue Za Zhi, 2011, 32(5):289293.
[16] Pui CH, Howard SC. Current management and challenges of malignant disease in the CNS in paediatric leukaemia[J]. Lancet Oncol, 2008, 9(3):257268.
[17] Feng S, Cen J, Huang Y, et al. Matrix metalloproteinase2 and 9 secreted by leukemic cells increase the permeability of bloodbrain barrier by disrupting tight junction proteins[J]. PLoS One, 2011, 6(8):e20599.
[18] Raanani P, Shpilberg O, BenBassat I. Extramedullary disease and targeted therapies for hematological malignanciesis the association real?[J]. Ann Oncol, 2007, 18(1):712.
[19] Tsukamoto S, Ota S, Ohwada C, et al. Extramedullary blast crisis of chronic myelogenous leukemia as an initial presentation[J]. Leuk Res Rep, 2013, 2(2):6769. |